Multidisciplinary approaches to supporting whole person gender affirming perioperative health and care

Fenway Health
March, 2020

Maddie Deutsch, MD, MPH
Associate Professor of Clinical Family & Community Medicine
Medical Director, UCSF Transgender Care
University of California – San Francisco
Outline

• Background on WPATH surgery clearance
• Holistic perioperative approaches
• Vaginoplasty
• Masculinizing chest surgery
• Phalloplasty
• Sexual Health
• Perioperative hormones
• Cases
WPATH Criteria – Are There Limitations?

• How to handle patients who lack access to appropriate mental health services?

• Does the process encourage patients to “game the system”?
  – While at the same time appearing to serve as a “gatekeeper”

• Does not include any explicit assessment of health literacy and psychosocial functioning
  – This becomes very important as MediCaid and safety net populations now also have access to such surgeries
Perioperative Care Navigation - Workflow

- Functional assessment
- “WPATH” assessment
  - Diagnosis
  - Eligibility & Readiness Assessment
  - Informed Consent
- Education & resources
- Reassessment
- Physical
- Emotional
- Infrastructure
- Knowledge base
- Housing
- Social & family support
- Psychosocial functioning
- Waiting list
- Recovery location?
- Transportation?
- Assistance?
- End of surgical phase
- Surgery & immediate postoperative care

Housing
Healthcare Literacy
Social & family support
Psychosocial functioning

Outcomes

• Studies seem to show 3 factors that place pts at risk of regret:
  – Major coexisting psychiatric conditions
  – Limited life-experience in the new gender role prior to surgery
  – Unsatisfactory surgical results

• Reduction in suicidality postop

• One of best predictors of postop QOL is quality of surgical results
Postoperative Complications following Primary Penile Inversion Vaginoplasty among 330 Male-to-Female Transgender Patients.

Gaither TW¹, Awad MA², Osterberg EC³, Murphy GP¹, Romero A⁴, Bowers ML⁴, Breyer BN⁵.

Supplementary Table. Post-surgical complications and median time to complication in MTF-SRS (n=330)

<table>
<thead>
<tr>
<th>Follow-up visit due to any complication</th>
<th>N (%)</th>
<th>Months from surgery, median (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>95 (28.7)</td>
<td>4.4 (1-11.5)</td>
</tr>
<tr>
<td>No</td>
<td>236 (71.5)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Complication</th>
<th>N (%)</th>
<th>Months from surgery, median (IQR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granulation tissue</td>
<td>24 (7.3)</td>
<td>4 (1-9)</td>
</tr>
<tr>
<td>Vaginal pain</td>
<td>17 (5.2)</td>
<td>6 (2-12)</td>
</tr>
<tr>
<td>Wound separation</td>
<td>17 (5.2)</td>
<td>0.6 (0.4-1)</td>
</tr>
<tr>
<td>Poor cosmetic appearance</td>
<td>16 (4.9)</td>
<td>11 (4-13)</td>
</tr>
<tr>
<td>Vaginal stenosis</td>
<td>10 (3.0)</td>
<td>19 (6-22)</td>
</tr>
<tr>
<td>Rectoureovaginal fistula</td>
<td>3 (0.9)</td>
<td>10.5 (2.4-18.6)</td>
</tr>
<tr>
<td>Vesicoureovaginal fistula</td>
<td>3 (0.9)</td>
<td>7.0 (3.9-10.7)</td>
</tr>
<tr>
<td>Deflecting urinary stream/dribbling</td>
<td>6 (1.8)</td>
<td>9 (4-19)</td>
</tr>
<tr>
<td>Infection</td>
<td>5 (1.5)</td>
<td>27 (5-50)</td>
</tr>
<tr>
<td>Vaginal fissure</td>
<td>2 (0.6)</td>
<td>23 (10-36)</td>
</tr>
<tr>
<td>Vaginal bleeding</td>
<td>2 (0.6)</td>
<td>3 (0.3-5)</td>
</tr>
<tr>
<td>Difficulty with dilation</td>
<td>3 (0.9)</td>
<td>8 (3-13)</td>
</tr>
<tr>
<td>Deep vein thrombosis/pulmonary embolism</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>
Postoperative Complications following Primary Penile Inversion Vaginoplasty among 330 Male-to-Female Transgender Patients.

Gaither TW¹, Awad MA², Osterberg EC³, Murphy GP¹, Romero A⁴, Bowers ML⁴, Breyer BN⁵.

- 9% reoperation rate

<table>
<thead>
<tr>
<th>Type of reoperation</th>
<th>Count (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labioplasty</td>
<td>19 (5.6)</td>
</tr>
<tr>
<td>Clitoroplasty</td>
<td>3 (1.0)</td>
</tr>
<tr>
<td>Urethroplasty</td>
<td>5 (1.5)</td>
</tr>
<tr>
<td>Debridement of granulation tissue</td>
<td>3 (1.0)</td>
</tr>
<tr>
<td>Vaginal bleeding</td>
<td>1 (0.3)</td>
</tr>
<tr>
<td>Vaginal repair**</td>
<td>4 (1.2)</td>
</tr>
<tr>
<td>Fistula repair</td>
<td>6 (1.8)</td>
</tr>
</tbody>
</table>

* Other includes follow-up for difficulty with dilation and constipation
** Vaginal fissure/stenosis
Overall complication rate 32.5% (N=1687)

Meato-urethral stricture 14.4%

Neovaginal stenosis 9.8%

Wound infection 3.2%

Less common:
  – Prolapse
  – Necrosis
  – RV fistula
• 72 of 77 pt attended at least 1 PT session
  – 42% had pelvic floor dysfxn
  – 37% had bowel dysfxn

• 69% of pelvic floor and 73% of bowel dysfxn resolved by first postop PT visit

• Postop pelvic floor dysfunction much lower in PT group (28% vs 86%m p<0.06)

• Hx of abuse strong predictor of floor dysfxn
  • 91% vs 31%, P<0.001
• 77% (31/40) had preop pelvic floor dysfunction

• 30 of 31 went to preop PT and 29 went to postop PT

• Surgery was not associated with development of pelvic floor dysfunction in those without it preop

• Statistically (clinically?) significant improvement in scores postop at 4 months.
20% of 54 trans women with neovaginas, median age 40, found to be positive for a high-risk HPV strain.

No lesions found.
• 36% had at least 1 of 6,11,16,18

• What does having types 6 or 11 mean with respect to vaginal lesion risk?

• Tissue used in vaginoplasty:
  – Penile
  – Scrotal
  – Urethral

Prevalence of human papillomavirus infection in a clinic sample of transsexuals in Italy.
Loverro G¹, Di Naro E¹, Caringella AM¹, De Robertis AL², Loconsole D², Chironna M².
Penile/Urethral Cancer

• Incidence in range of 1/100,000 for penile, 4/1,000,000 for urethral

• Risk factors include
  – HPV (including type 6 for penile)
  – Trauma
  – Chronic inflammation
  – Lichen sclerosis, smegma? (penile)
Clinical Characteristics and Management of Neovaginal Fistulas After Vaginoplasty in Transgender Women.

van der Sluis WB¹, Bouman MB, Buncamper ME, Pijot GL, Mullender MG, Meijerink WJ.

- 2.3% rate in N=1082 collected over 25 years
Table 1. Incidence of Neovaginal Fistulas in Transgender Women Who Required Surgical Treatment Between 1990 and 2015

<table>
<thead>
<tr>
<th>Fistula Type</th>
<th>Total Patients (n=1,082)</th>
<th>Penile Inversion Vaginoplasty (n=997)</th>
<th>Primary Bowel Vaginoplasty (n=40)</th>
<th>Revision Vaginoplasty (n=80)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total fistulas</td>
<td>25 (2.3, 1.5–3.4)</td>
<td>19 (1.9, 1.1–3.0)</td>
<td>0 (0.0, 0.0–9.2)</td>
<td>6 (7.5, 2.8–16.3)</td>
</tr>
<tr>
<td>Rectoneovaginal</td>
<td>13 (1.2, 0.6–2.1)</td>
<td>8 (0.8, 0.3–1.6)</td>
<td>0 (0.0, 0.0–9.2)</td>
<td>5 (6.3, 2.0–14.6)</td>
</tr>
<tr>
<td>Urethroseovaginal</td>
<td>11 (1.0, 0.5–1.8)</td>
<td>10 (1.0, 0.5–1.8)</td>
<td>0 (0.0, 0.0–9.2)</td>
<td>1 (1.3, 0.0–7.0)</td>
</tr>
<tr>
<td>Pouch-neovaginal</td>
<td>1 (0.1, 0.0–0.5)</td>
<td>1 (0.1, 0.0–0.6)</td>
<td>0 (0.0, 0.0–9.2)</td>
<td>0 (0.0, 0.0–4.6)</td>
</tr>
</tbody>
</table>

Data are n (%), 95% confidence interval.

Clinical Characteristics and Management of Neovaginal Fistulas After Vaginoplasty in Transgender Women

Wouter B. van der Sluis, MD, Mark-Bram Bouman, MD, Marlon E. Buncamper, MD, Garry L.S. Pigot, MD, Margriet G. Mullender, Ph.D, and Wilhelms J.H.J. Meijerink, MD, Ph.D

(Obstet Gynecol 2016;127:1118–26)
Fig. 3. Voiding cystourethrogram showing a urethronovaginal fistula of the penile skin-lined neovagina in a 36-year-old transgender woman.


Fig. 2. Endoscopic examination of the sigmoid-derived neovagina in a 28-year-old transgender woman showing fecal matter around the rectoneovaginal fistula entrance.

Fig. 1. Computed tomography scan using rectal contrast showing a rectoendovaginal fistula (arrow) of the penile skin-lined neovagina in a 26-year-old transgender woman. Depicted are transverse (A) and coronal (B) planes.

Figure 2  Example of a urethral meatus pointing forwards, with a bulky corpus spongiosum remnant.
Urinary stream problems

• Weak or deflecting stream

• Consider urethral stenosis, assymetric labia, adhesion band

• Often requires revision surgery
Neovaginal hair

• Remove with a forcep

• Hair removal cream – patch test first
STI screening after vaginoplasty?

• Penile inversion technique – skin lined vagina
  – ? Urethral mucosa used

• Sigmoid colon vaginoplasty
  – Less common
  – Mucosa
Neovaginal Flora

- 50 trans women evaluated by a variety of microbiological techniques
- 1/50 showed lactobacilli
- Mean pH 5.8
- No candida
- Mix of skin, colonic, vaginal / BV flora
- No association between sx and any species

*Microflora of the penile skin-lined neovagina of transsexual women*

Steven Weyers¹, Hans Verstraelen¹, Jan Gerris¹, Stan Monstrey², Guido dos Santos Lopes Santiago³, Bart Saerens³, Ellen De Backer³, Geert Claeys³, Mario Vaneechoutte⁴ and Rita Verhelst⁴

Approach to neovaginal discharge

- Skin-lined cavity
- pH = neutral
- Does not self-clean
  - sebum, dead skin, lubricant, ejaculate
- “Normal” flora?
- Skin infection vs vaginal infection
- Fistula?
- Use an anoscope for exam
Granulation Tissue

- Fibroblastic connective tissue laying down new connective (scar) tissue matrix
- Inflammatory but not infected (usually)
- Silver nitrate
- Moderate potency topical steroid
Other Post-Vaginoplasty Issues

- Persistent/excess erectile tissue
- Urinary stress/urge incontinence
  - Prostatic changes?
- UTI
- Hematoma
- Colonic vaginoplasty considerations


Vaginoplasty Complications.
• Case series (N=100)

• Single surgeon

• No statistical association between hematoma and T use
Top Surgery Postoperative Care

• Dressings

• Binder for 4-6 weeks

• Scars
  – Hypertrophic -> kenalog?
Seroma/Hematoma Office Management

• Simple percutaneous drainage

• Can consult with surgeon
Phalloplasty Complications – Contributing Factors

- Flap design that includes tubularization of tissue (1–2 times) with an associated increased risk for ischemia
- Dependent, unstable position
- Colonized, moist recipient site
- Area of major friction during ambulation
- Acting as urinary conduit


Phalloplasty Flap-Related Complication.

Esmonde N1, Bluebond-Langner R2, Berli JU3.
Possible Postop Complication Syndromes – Phalloplasty

- Full phallic loss
- Partial flap loss
- Urethral loss
- Infection
- Hematoma
- Wound dehiscence
- Miscellaneous
Phalloplasty – Urologic Complications

• Strictures (25%-58%)

• Urinary pooling 2/2 urethral irregularities and non-laminar flow

• Lifelong urologic follow-up recommended


Urologic Complications After Phalloplasty or Metoidioplasty.

Nikolavsky D1, Hughes M2, Zhao LC3.
Best matches for (estrogen or estradiol or hormone) perioperative thromboembolism:

**Perioperative Management of Female Hormone Medications.**

**European guidelines on perioperative venous thromboembolism prophylaxis: Surgery in the elderly.**

**Anesthesia in adults with congenital heart disease.**
• Only single mention of estrogen

• Over age 70, “consider addressing” (Grade 2C)
• Systematic review identified 18 studies

• Quality of studies was mixed

“There is insufficient evidence to support routine discontinuation of testosterone or spironolactone in transgender patients undergoing scheduled surgical procedures. Given inconsistent risk data about the risks associated with estrogen, decisions about whether or not to discontinue estrogen treatment should keep individual risk factors and concerns in mind”
Perioperative Management of Female Hormone Medications.
Seim LA¹, Irizarry-Alvarado JM¹.

• Review of literature

Conclusion: “Until additional studies are performed, the risks and benefits must be weighed on an individual basis with consideration of prophylaxis when a decision is made to continue these medications in the perioperative period. Part of this decision making includes the risk of fetal harm in an unwanted pregnancy in preparation for nonobstetric surgery versus an increased risk of venous thromboembolism.”
Postmenopausal hormone replacement and venous thromboembolism following hip and knee arthroplasty.

Hurbanek JG¹, Jaffer AK, Morra N, Karafa M, Brotman DJ.

- 108 cases matched to 210 controls
- No association between menopausal HRT and clot risk.

Conclusion: “We found no association between perioperative hormone replacement and post-operative thrombosis in patients undergoing major orthopaedic surgery. Routine discontinuation of these medications preoperatively--and possibly in other situations predisposing to thrombosis, such as acute medical illness--may be unnecessary in patients receiving appropriate pharmacologic antithrombotic prophylaxis.”
Review article

Discusses several studies that failed to find a difference, and one with odds ratio 3.3

They then conclude (how?): “Ultimately, it should be advocated that combined or single-medication oral contraceptive therapy and hormone-replacement therapy be held for 4 to 6 weeks before surgery and restarted at least 2 weeks after surgery or once the patient is fully ambulatory.”
Care abroad

• Thailand
• Europe
• Mexico
Sexual Health

• What is a clitoris?

• How does orgasm work without penetration/ejaculation?

• What parts of my neophallus are erogenously sensitive?
Sexual Function Post Vaginoplasty

- Poor sexual function before surgery is a reliable predictor of poor sexual function after surgery.

- Patients with difficulty or lack of experience achieving erogenous genital sensation should be encouraged to self-stimulate before their surgery.

- Depression, performance anxiety, and chronic pain interfere with recovery of erogenous sensation and/or orgasm after vaginoplasty.

- Neuroplasticity, gray-matter changes and synapses strengthen in response to new stimuli and repetition.
Case 1

• 28 y/o trans woman with clitoral pain on arousal.

• Severe pain limiting daily function

• Pt has significant behavioral health comorbidities

• Exam shows point tenderness in clitoral area, otherwise normal
Case 2

• 33 y/o transgender woman with introitus pain, especially with arousal

• Exam shows excess tissue in area of introitus

• Referred back to surgeon -> excess erectile tissue
Case 3

• 39 y/o transgender man for preop for phalloplasty with outside private office

• Pt has PPO and has worked directly with surgeon office up to this point, now here for me to “sign the papers”
Case 3

• Pt has long hx recurrent dysuria with negative u/a but has had various cultures come back over the years with <10,000 cfu of several organisms

• Has not discussed this or disclosed this to the urologist
Case 4

• 22 y/o trans man has top surgery in another state

• Now 2 weeks postop and has developed a hematoma. He is worried about cosmesis. What do you do?
Case 5

- 66 year old transgender woman with TBI, moderate cognitive impairment, anxiety, depression, and PTSD
- Often is confused, sometimes confabulates, and very limited memory
- Lives alone in SRO, no reliable social support. “Has friends” but does not know their names
- Wants vaginoplasty and FFS
- Going for oral surgery and thinks that surgeon told her to stop her hormones for 6 weeks before surgery.
Case 6

• Transgender man, 28 y/o, going for oophorectomy.

• “Should I leave one of my ovaries? The Ob-Gyn said I should because it will lower my risk of osteoporosis and heart disease”.
Case 7

• Transfeminine person 55 y/o never on hormones, does not want to take them
• Wants orchiectomy only
Case 7

- Transfeminine person 55 y/o never on hormones, does not want to take them
- Wants orchiectomy only

- What if this person was 35?
Case 7

- Transfeminine person 55 y/o never on hormones, does not want to take them
- Wants orchiectomy only

- What if this person was 35?

- What if on hormones but T level is 330 pre-op?
Case 8

• “My (surgeon/friend/someone on Reddit) told me I can (lower/stop/cut in half) my hormone dose after (orchiectomy/vaginoplasty/oopherectomy) – is this true?